SCHEMBL4892485

SCHEMBL4892485

COc1ccccc1C(=O)Nc1ccc(Nc2nccc(-c3ccccn3)n2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 3/20 0.62
ABL1 P00519 2/20 0.62
PDGFRB P09619 2/20 0.62
BCR P11274 2/20 0.62
PDGFRA P16234 2/20 0.62
EGFR P00533 1/20 0.62
RXFP1 Q9HBX9 1/20 0.58
SYK P43405 3/20 0.55
AURKA O14965 1/20 0.55
AURKB Q96GD4 1/20 0.55
RAB9A P51151 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
NPC1 O15118 2/20 0.54
TP53 P04637 2/20 0.54
MEN1 O00255 1/20 0.54
GAA P10253 1/20 0.54
KMT2A Q03164 1/20 0.54
MAPT P10636 3/20 0.53
ALDH1A1 P00352 1/20 0.53
MAPK1 P28482 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4901273 0.87 ABL1 (0.76) PRKCAABL1PDGFRBBCRPDGFRA
SCHEMBL4903410 0.86 ABL1 (0.69) PRKCAABL1PDGFRBBCRPDGFRA
SCHEMBL4892567 0.85 ABL1 (0.84) PRKCAABL1PDGFRBBCRPDGFRA
SCHEMBL4891611 0.85 MEN1 (0.60) PRKCAABL1BCRSYKSMN1; SMN2
SCHEMBL4901565 0.82 MEN1 (0.59) PRKCARXFP1SYKMEN1KMT2A
SCHEMBL4903298 0.81 ABL1 (0.59) PRKCAABL1PDGFRBBCRPDGFRA
SCHEMBL7461995 0.81 JAK2 (0.73) SYKAURKAJAK2JAK3
SCHEMBL4899630 0.78 ABL1 (0.64) PRKCAABL1PDGFRBBCRPDGFRA
SCHEMBL7469378 0.78 PIK3CA (0.62) SYKAURKBRAB9ANPC1MEN1
SCHEMBL4903134 0.78 ABL1 (0.84) PRKCAABL1PDGFRBBCRPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US claimed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP claimed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO claimed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP disclosed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP PRKCA 2607/4885ABL1 2843/4885PDGFRB 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.